- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00589082
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.
Overall results in the treatment of middle aged adults acute myelogenous leukemia (AML) are substantially improved in the last decade, with complete remission (CR) rates established to values of 70 to 80per cent and also encouraging long-term outcome, especially in patients who can tolerate intensified post remissional treatment strategies. On the contrary, there has been little progress in the treatment of older patients. In these patients the response rate generally range between 40 and 60per cent, and overall survival at 2 years is often less than 10 per cent.
Usually, a combination of anthracyclines daunomycin DNR or doxorubicin and cytarabyne Ara-C has been utilized for the remission-induction treatment, with schedules similar to those utilized in younger cases, for patients eligible to intensive treatments. Variation of the dose of DNR has not brought any significant benefit. The EORTC HOVON randomized trial AML9 compared two drugs in induction for previously untreated patients. DNR versus Mithoxantrone (MTZ). MTZ induction therapy produces a slightly better CR rate than DNR-containing regimen (47per cent vs 38per cent, P equals 0.069), without any significant effect on remission duration and survival. The DFS probability between the two treatment arms was not different. The median DFS estimates were 39 weeks in both groups. The DFS rate at 5 years was 8per cent. Also the duration of survival was similar (p equals 0.23) in the two treatment groups. Median survival estimates were 36 weeks (DNR) and 39 weeks (MTZ). The percentage of patients still alive at 5 years were 6per cent and 9per cent respectively.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Previously untreated AML (including AML after MDS) with > 20% marrow blasts (new WHO classification)
- Age ≥ 61 <75 years
- AML evoluted after MDS are eligible if not previously treated with antiblastic drugs.
- Performance status ≥ 70 (Karnofsky) or ≤ 2 (WHO)
- Signed informed consent from the patient
Exclusion Criteria:
Version 3.0 - february 2001 - CONFIDENTIAL 9
- Patients already treated for their AML with other cytotoxic drugs (except no more than 7 days of Corticosteroids)
- Acute promyelocitic leukemia (FAB M3 or M3v)
- Blast crisis of chronic myeloid leukemia or leukemia supervening after other
- myeloproliferative disease
- Concomitant progressive malignant disease
- Presence of meningeal disease
- History of recent myocardial infarction (within previous 12 months), significant congestive heart failure, life threatening arrhythmia, or cardiovascular disease of Class II or greater according to the New York Heart Association Functional Classification (NYHAFC).
- Abnormal cardiac ejection fraction (45% or less).
- Abnormal hepatic function (ALAT/ASAT or bilirubin >3 N ).
- Abnormal renal function (creatinine >3 N)
- Active bacterial, fungal or viral infection as documented by positive cultures, radiological imaging, clinical signs, septic fever or septic shock symptoms.
- Patients who recover from the infection could be eligible.
- History of hypersensitivity to one of the liposomal constituents.
- Severe pulmonary, neurological or psychiatric disease.
- People unable to give informed consent.
- Presence of any phychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule.
- HIV positivity
- Intercurrent organ damage or medical problems that would interfere with therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
standard 3+7
|
|
Experimental: 2
DNX 3+7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Efficacy and safety of DaunoXome in association with cytosine arabinoside in terms of reduction of induction deaths respect to standard "3+7" chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy, in terms of DFS, of maintenance therapy with low-dose of Ara-C plus ATRA versus no maintenance therapy
|
Collaborators and Investigators
Investigators
- Principal Investigator: Franco MANDELLI, Prof, Università di Roma "La Sapienza"
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GSI 103-AMLE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
-
Turkish Leukemia Study GroupCompleted
Clinical Trials on Daunorubicine
-
Gruppo Italiano Malattie EMatologiche dell'AdultoUnknown
-
Uwe PlatzbeckerGilead SciencesWithdrawnAcute Myeloid Leukemia | Myelodysplastic Neoplasm
-
Assistance Publique - Hôpitaux de ParisFrench Innovative Leukemia Organisation; Acute Leukemia French AssociationCompleted
-
Hannover Medical SchoolUniversity Hospital, Ghent; Johann Wolfgang Goethe University Hospital; University... and other collaboratorsUnknownDe Novo Akute Myeloid Leukemia (AML) | Secondary Acute Myeloid Leukemia (AML) | Refractory Anemia With Excess of Blasts in TransformationGermany
-
Poitiers University HospitalNovartis; Ministry of Health, FranceTerminatedChronic Myeloid LeukemiaFrance
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Acute Leukemia French AssociationHospices Civils de LyonCompleted
-
Sumitomo Pharma Co., Ltd.CompletedAcute Myeloid LeukemiaJapan
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompleted